NDA submitted for Brilinta for acute coronary syndromes - MPR

Links shared publicly online about this topic.

1,591
total visits

NDA submitted for Brilinta for acute coronary syndromes - MPR

AstraZeneca announced that it has submitted a New Drug Application (NDA) to the FDA for Brilinta (ticagrelor), an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

View full resource at empr.com

Tags: Disease and Condition, Drug, FDA, Anti-Clotting Medication, Brilinta, AstraZeneca, News

Most Recently Shared on November 19, 2009 at 6:59 pm By:

MPR

MPR News: NDA submitted for Brilinta for acute coronary syndromes: AstraZeneca announced that it has submitted a Ne... http://bit.ly/1krEQx

2 years ago...

Retweet

Favorite

New Drug Application for ticagrelor submitted to the FDA

news-medical.net — “AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).” View full resource at news-medical.net